Authorization to extend HLA PGD
Published on 14 May 2025
The Agence de la biomédecine is competent to issue authorizations for the extension of preimplantation diagnosis for therapeutic purposes on an experimental basis (L. 2131-4-1 of the French Public Health Code).
The aim of PGD, combined with HLA typing, is to enable the conception of a child who is free of the family genetic disease that has afflicted his or her elder sibling, and is likely to be able to treat this sick sibling definitively, thanks to stem cells from placental blood taken from the umbilical cord or, later, from bone marrow.
Request for authorization
The request for diagnosis, made by a couple, is sent to the Agence de la biomédecine by the CPDPN following the couple, according to a standard file whose composition is set by the Agence's Director General.
On a case-by-case basis, the Director of the Agency authorizes this diagnosis if the couple's situation justifies it in the light of the strict conditions laid down by the legislator. The Director's decision is based on the advice of her Advisory Board.
To be sent electronically to juridique@biomedecine.mssante.fr (this address may only be used by a healthcare professional) and in 2 copies to :
1 avenue du Stade de France 93212 Saint-Denis La Plaine Cedex
Share